A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer

BACKGROUND: FOLFIRINOX (FX) has been reported as an effective treatment for unresectable advanced pancreatic cancer. However, FX is associated with a high incidence of adverse events (AEs). A previous phase II study in Japan showed high incidences of hematological AEs, including febrile neutropenia...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Kensaku, Iwashita, Takuji, Uemura, Shinya, Maruta, Akinori, Okuno, Mitsuru, Ando, Nobuhiro, Iwata, Keisuke, Kawaguchi, Junji, Mukai, Tsuyoshi, Shimizu, Masahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762326/
https://www.ncbi.nlm.nih.gov/pubmed/29340058
http://dx.doi.org/10.18632/oncotarget.22795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762326/
https://www.ncbi.nlm.nih.gov/pubmed/29340058
http://dx.doi.org/10.18632/oncotarget.22795

Ejemplares similares